Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia

Annals of Pharmacotherapy

Volumn 43, Issue 1, 2009, Pages 19-27

  Keegan, Shaun P ^a,b   Gallagher, Erika M ^a   Ernst, Neil E ^b,c   Young, Emily J ^b,c   Mueller, Eric W ^b,c  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c University Hospital   (United States)

Author keywords

Argatroban; Multiple organ failure; Thrombocytopenia

Indexed keywords

ARGATROBAN; HEPARIN; ANTICOAGULANT AGENT; PIPECOLIC ACID DERIVATIVE;

ADULT; AGED; APACHE; ARTICLE; COHORT ANALYSIS; CRITICAL ILLNESS; DOSE RESPONSE; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT RESPONSE; BLOOD; CHEMICALLY INDUCED; COMPARATIVE STUDY; MIDDLE AGED; THROMBOCYTOPENIA;

ADULT; AGED; ANTICOAGULANTS; COHORT STUDIES; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PIPECOLIC ACIDS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 58549108988     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L224     Document Type: Article

References (25)

1. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-7.
2. Brieger DB, Mak K-H, Kottke-Marchant K, Topol EJ. Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998;31:1449-59.
3. Nand S, Wong W, Yuen B, Yetter A, Schmulbach E, Gross Fisher S. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1997;56:12-6.
4. Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007;35:1165-76.
5. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol 1998;35:9-16.
6. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 2005;127:1857-61.
7. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment and prevention. Chest 2004;126(suppl):311S-37S.
8. Product information. Argatroban (argatroban). Research Triangle Park, NC: GlaxoSmithKline, April 2008.
9. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-43.
10. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003;163:1849-56.
11. Williamson DR, Boulanger I, Tardif M, Albert M, Gregoire G. Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy 2004;24:409-14.
12. Reichert MG, MacGregor DA, Kincaid EH, Dolinski SY. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother 2003;37:652-4. DOI 10.1345/aph.1C187
13. Kodityal S, Nguyen PH, Kodityal A, Sherer J, Hursting MJ, Rice L. Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital. J Intensive Care Med 2006;21:86-92.
14. Beiderlinden M, Treschan TA, Görlinger K, Peters J. Argatroban anticoagulation in critically ill patients. Ann Pharmacother 2007;41:749-54. Epub 17 Apr 2007. DOI 10.1345/aph.1H569
15. Baghdasarian SB, Singh I, Militello MA, et al. Argatroban dosage in critically ill patients with HIT (abstract 493). Blood 2004;104:493a.
16. Wester JP, Haas FJ, Biesma DH, Leusink JA, Veth G. Thrombosis and hemorrhage in heparin-induced thrombocytopenia in seriously ill patients, intensive Care Med 2004;30:1927-34.
17. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
18. Ferreria FL, Bota DP, Brass A, Melot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001;286:1754-8.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
20. Arpino PA, Hallisey RK. Effect of renal function on the pharmacodynamics of argatroban. Ann Pharmacother 2004;38:25-9. DOI 10.1345/aph.1D163
21. Levine LR, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 2006;129:1167-75.
22. Kiser TH, Jung R, MacLaren R, Fish DN. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy 2005;25:1736-45.
23. Guidelines Committee. Society of Critical Care Medicine. Guidelines for ICU admission, discharge, and triage. Crit Care Med 1999;27:633-8.
24. Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA. Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy 2007;27:564-87.
25. Siegmund R, Boer K, Poeschel K, Wolf G, Deufel T, Kiehntopf M. Comparison of the ecarin chromogenic assay and different aPTT assays for the measurement of argatroban concentrations in plasma from healthy individuals and from coagulation deficient patients. Thromb Res 2008;123:159-65. Epub 21 Apr 2008. DOI 10.1016/j.thromres.2008.02.013